Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZL-61
- Development stage
- Preclinical
- Lead developer
- Zenitar
- Modality
- Small Molecules
01
Overview
ZL-61 is a small-molecule multi-kinase inhibitor developed by Chengdu Zenitar Biomedical Technology. It is designed to target Janus kinase 2 (JAK2), Fms-like tyrosine kinase 3 (FLT3), and Cyclin-dependent kinase 6 (CDK6). By inhibiting these key signaling pathways, ZL-61 aims to treat a variety of hematologic malignancies and myeloproliferative neoplasms. Its development focus includes Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET) via JAK2 inhibition; relapsed or refractory FLT3-positive Acute Myeloid Leukemia (AML) via FLT3 inhibition; and relapsed or refractory B-cell lymphomas, including Diffuse Large B-Cell Lymphoma (DLBCL), via CDK6 inhibition.
02
Targets
Beyond the preview
Go deeper on ZL-61.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZL-61.